← boardnext 2026-08
HLN
HALEONdistress 0/10 · well-funded / low risk$9.68-2%today-14% from 52w high
Lead: Dentin Hypersensitivity
Revenue
$11030M
Liquidity
$1260M
Runway
—
Shares 1y
0%
Price & events
-5.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-4.3%
1W
+8.1%
1M
+1.5%
3M
-6.3%
6M
+1.2%
1Y
+13.4%
2Y
—
5Y
+40.9%
All
Overview
- Market Cap
- $86.61B
- Enterprise Value
- $93.02B
- Volume
- 1.06M
- 52 Week Range
- $8.70 – $11.27
- Total Shares
- 8.95B
- Float Shares
- 4.44B
- Short %
- 0.32%
- % Held by Insiders
- 0.01%
- % Held by Institutions
- 13.28%
- RVOL
- 0.11x
- Beta
- 0.24
Pipeline stages · 1 programs
Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassiu
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassiu | Dentin Hypersensitivity | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-07-30Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $12 (+20% upside) · 5 analysts
- 2026-01-23BarclaysEqual-Weight → Overweight
- 2025-09-16BarclaysOverweight → Equal-Weight
- 2024-09-20Morgan StanleyOverweight
Competitors — Dentin Hypersensitivity
- none identified
Recent news
- 2026-07-22Haleon (HLN) H2 2025 earnings summary - Quartr
- 2026-07-21Haleon stock trades steadily as consumer health earnings and cash flow support valuation - Ad-hoc-news.de
- 2026-07-21Sabrina Sharpe Appointed VP Global Brand Lead for Polident, Poligrip & Corega at Haleon - hrtoday.in
- 2026-07-20Haleon plc (HLN) Stock Analysis: Unlocking a Potential 15.35% Upside in the Healthcare Sector - DirectorsTalk Interviews
- 2026-07-20Haleon PLC (HLN.L) Stock Report: Navigating Growth With A 10.97% Upside Potential - DirectorsTalk Interviews
- 2026-07-19Haleon (HLN) H2 2024 earnings summary - Quartr
- 2026-07-18Haleon (HLN) H1 2024 (Q&A) earnings summary - Quartr
- 2026-07-18Haleon plc (HLN) Stock Analysis: Unveiling 19.36% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.